Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07133425 | A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer | PHASE2 | RECRUITING | 29 | — | — | Nov 6, 2025 | Feb 1, 2030 | May 20, 2026 | 1 | United States |
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Phase II biomarker study of SAR445877 | EXPERIMENTAL | Will receive SAR445877 by vein over about 60 minutes every 2 weeks, on Day 1 of each 14-day cycle. |
| Name | Type | Description |
|---|---|---|
| SAR445877 | DRUG | Given by IV |
Eligibility Criteria 1. Ability to understand and willingness to sign informed consent form (ICF) prior to initiation of the study and any study procedures. 2. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SAR445877 in participants \<18 years of age, c...